U.S. Markets close in 2 hrs 11 mins
  • S&P 500

    4,431.63
    -42.12 (-0.94%)
     
  • Dow 30

    34,540.47
    -210.85 (-0.61%)
     
  • Nasdaq

    15,012.37
    -169.55 (-1.12%)
     
  • Russell 2000

    2,229.00
    -3.91 (-0.18%)
     
  • Crude Oil

    71.82
    -0.79 (-1.09%)
     
  • Gold

    1,751.00
    -5.70 (-0.32%)
     
  • Silver

    22.42
    -0.33 (-1.44%)
     
  • EUR/USD

    1.1732
    -0.0040 (-0.3402%)
     
  • 10-Yr Bond

    1.3680
    +0.0370 (+2.78%)
     
  • Vix

    20.73
    +2.04 (+10.91%)
     
  • GBP/USD

    1.3744
    -0.0052 (-0.3793%)
     
  • USD/JPY

    109.9400
    +0.2220 (+0.2023%)
     
  • BTC-USD

    47,459.88
    -203.87 (-0.43%)
     
  • CMC Crypto 200

    1,204.60
    -20.93 (-1.71%)
     
  • FTSE 100

    6,963.64
    -63.84 (-0.91%)
     
  • Nikkei 225

    30,500.05
    +176.71 (+0.58%)
     

Novavax to Participate in Fireside Chat at SVB Leerink CybeRx Series: Vaccine Forum

  • Oops!
    Something went wrong.
    Please try again later.
·2 min read
In this article:
  • Oops!
    Something went wrong.
    Please try again later.

GAITHERSBURG, Md., June 17, 2021 /PRNewswire/ -- Novavax, Inc. (Nasdaq: NVAX), a biotechnology company developing next-generation vaccines for serious infectious diseases, today announced that it will participate in a fireside chat during the upcoming 2nd Annual CybeRx Series: Vaccine Forum. Novavax' recombinant nanoparticle protein-based COVID-19 vaccine candidate, NVX-CoV2373, will be a topic of discussion.

Fireside chat details:

Date:

Tuesday, June 22, 2021

Time:

11:00 – 11:50 a.m. Eastern Time (ET)

Moderator:

Geoffrey Porges, M.B.B.S.

Novavax participants:

Gregory M. Glenn, M.D., President, Research and Development and John J. Trizzino, Chief Commercial Officer, Chief Business Officer and Interim Chief Financial Officer

Please contact your SVP Leerink representative to view the session.

About Novavax

Novavax, Inc. (Nasdaq: NVAX) is a biotechnology company that promotes improved health globally through the discovery, development and commercialization of innovative vaccines to prevent serious infectious diseases. The company's proprietary recombinant technology platform combines the power and speed of genetic engineering to efficiently produce highly immunogenic nanoparticles designed to address urgent global health needs. Novavax is conducting late-stage clinical trials for NVX-CoV2373, its vaccine candidate against SARS-CoV-2, the virus that causes COVID-19. NanoFlu™, its quadrivalent influenza nanoparticle vaccine, met all primary objectives in its pivotal Phase 3 clinical trial in older adults and will be advanced for regulatory submission. Both vaccine candidates incorporate Novavax' proprietary saponin-based Matrix-M™ adjuvant to enhance the immune response and stimulate high levels of neutralizing antibodies.

For more information, visit www.novavax.com and connect with us on Twitter and LinkedIn.

Contacts:
Investors
Novavax, Inc.
Erika Schultz | 240-268-2022
ir@novavax.com

Solebury Trout
Alexandra Roy | 617-221-9197
aroy@soleburytrout.com

Media
Alison Chartan | 240-720-7804
Laura Keenan | 202-709-7521
Amy Speak | 617-420-2461
media@novavax.com

Novavax Logo (PRNewsfoto/Novavax)
Novavax Logo (PRNewsfoto/Novavax)
Cision
Cision

View original content to download multimedia:http://www.prnewswire.com/news-releases/novavax-to-participate-in-fireside-chat-at-svb-leerink-cyberx-series-vaccine-forum-301315044.html

SOURCE Novavax, Inc.